+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 6Years - 17Years
All Genders
ID05156398

Phase 3 Randomized Study of Rimegepant Versus Placebo for Preventing Migraine in Children and Adolescents Aged 6 to Under 18 Years

Led by Pfizer · Updated on 2026-10-14

640

Participants Needed

93

Research Sites

187 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of rimegepant compared to a placebo as a preventative treatment for children and adolescents aged 6 to under 18 years with episodic migraine. The study focuses on reducing the number of migraine days per month and improving quality of life in this young population. It is a Phase 3, randomized, double-blind, placebo-controlled trial sponsored by Pfizer. Participants receive either rimegepant in doses of 75mg or 50mg two 25mg orally disintegrating tablets or a matching placebo with the same dosing options. The study uses a double-blind design over a 12-week treatment phase to compare outcomes. The research also monitors safety and tolerability for up to 72 weeks, including the frequency of liver-related adverse events. During the study, participants will have assessments to record migraine days and severity, use of acute migraine medications, and quality of life using the Pediatric Quality of Life Inventory. Researchers will track safety through ongoing monitoring for adverse effects. The primary measure is the change in mean monthly migraine days over 12 weeks, with additional evaluations during the first 4 weeks and longer-term safety follow-up. Total participation may last up to 72 weeks for safety evaluation.

CONDITIONS

Brief Title

Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

Research Team

P

Pfizer Pfizer CT.gov Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here